What drove MGX's EPS surge in Q2 2024?

Metagenomi (MGX) experienced a significant decline in its EPS, with a value of -$0.29 reported for Q2 2024. Therefore, it is not accurate to claim that there was an "EPS surge." However, if you are asking what factors contributed to the negative EPS, I can provide an analysis based on available data.

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|MGX|MGX.O|Metagenomi|2023 Q3||-5.82|185|
|MGX|MGX.O|Metagenomi|2024 Q1|74.89451476793249|-1.19|185|
|MGX|MGX.O|Metagenomi|2024 Q2|92.40837696335078|-0.29|185|

Unfortunately, there is no available data or information regarding the specific factors that contributed to MGX's negative EPS in Q2 2024. It is important to note that EPS can be negatively impacted by various factors such as increased expenses, lower revenue, or one-time events. Without further information, it is difficult to provide a more detailed analysis. I recommend reviewing MGX's financial reports, press releases, and market analyses for more insights.